dc.creator | Rivero-Juárez, Antonio | es |
dc.creator | Mira, Jose A. | es |
dc.creator | Santos-Gil, Ignacio De Los | es |
dc.creator | López Cortés, Luis Fernando | es |
dc.creator | Girón-González, José-Antonio | es |
dc.creator | Márquez, Manuel | es |
dc.date.accessioned | 2019-02-26T13:38:55Z | |
dc.date.available | 2019-02-26T13:38:55Z | |
dc.date.issued | 2013 | |
dc.identifier.citation | Rivero-Juarez, A., Mira, J.A., Santos-Gil, I.D.L., López Cortés, L.F., Girón-González, J. y Márquez, M. (2013). Atazanavir-Based Therapy Is Associated with Higher Hepatitis C Viral Load in HIV Type 1-Infected Subjects with Untreated Hepatitis C. | |
dc.identifier.uri | https://hdl.handle.net/11441/83506 | |
dc.description | Comunicación corta | es |
dc.description.abstract | We assessed the relationship between atazanavir (ATV)-based antiretroviral treatment (ART) and plasma hepatitis C virus (HCV) viral load in a population of HIV/HCV-coinfected patients. HIV/HCV-coinfected patients who received ART based on a protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor (NNRTI) were included. Patients were stratified by ART drug [ATV/rtv, lopinavir (LPV/rtv), efavirenz (EFV), nevirapine (NVP), and other PIs], HCV genotype (1/4 and 2/3), and IL28B genotype (CC and non-CC). The Kruskal-Wallis test and chi-squared test were used to compare continuous and categorical variables, respectively. Multivariate analysis consisted of a stepwise linear regression analysis. Six hundred and forty-nine HIV/HCV-coinfected patients were included. HCV genotype 1/4 patients who received ATV had higher HCV RNA levels [6.57 (5.9-6.8) log IU/ml] than those who received LPV [6.1 (5.5-6.5) log IU/ml], EFV [6.1 (5.6-6.4) log IU/ml], NVP [5.8 (5.5-5.9) log IU/ml], or other PIs [6.1 (5.7-6.4) log IU/ml] (p=0.014). This association held for the IL28B genotype (CC versus non-CC). The association was not found in patients carrying HCV genotypes 2/3. The linear regression model identified the IL28B genotype and ATV use as independent factors associated with HCV RNA levels. ATV-based therapy may be associated with a higher HCV RNA viral load in HIV/HCV-coinfected patients. | es |
dc.format | application/pdf | es |
dc.language.iso | eng | es |
dc.relation.ispartof | null | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Atazanavir | es |
dc.subject | Hepatitis C | es |
dc.subject | HIV Type 1 | es |
dc.title | Atazanavir-Based Therapy Is Associated with Higher Hepatitis C Viral Load in HIV Type 1-Infected Subjects with Untreated Hepatitis C | es |
dc.type | info:eu-repo/semantics/other | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.identifier.doi | 10.1089/aid.2012.0126 | es |
dc.contributor.group | Universidad de Sevilla. CTS-203: Estudio de las Enfermedades Infecciosas | es |
idus.format.extent | 3 | es |